Medifast Stock Analysis


USD 120.17  0.13  0.11%   

Medifast price dip over the last few months may encourage shareholders to take a closer look at the firm as it is trading at a share price of 120.17 on 48,700 in trading volume. The company management teams were not very successful in positioning the firm resources to exploit market volatility in October. However, diversifying your holdings with Medifast or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.08. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Medifast partners.
Additionally, see Correlation Analysis.
The Medifast stock analysis report makes it easy to digest most publicly released information about Medifast and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Medifast Stock analysis module also helps to analyze the Medifast price relationship with some important fundamental indicators such as market cap and management efficiency.

Medifast Stock Analysis Notes

About 90.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.54. Medifast recorded earning per share (EPS) of 8.68. The entity last dividend was issued on the 19th of September 2022. The firm had 1:20 split on the February 14, 2011. Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company was founded in 1980 and is headquartered in Baltimore, Maryland. Medifast operates under Personal Services classification in the United States and is traded on New York Stock Exchange. It employs 984 people. To find out more about Medifast contact Michael MacDonald at 410 581-8042 or learn more at

Medifast Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Medifast's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Medifast or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Medifast generated a negative expected return over the last 90 days
Medifast has high historical volatility and very poor performance
Medifast is unlikely to experience financial distress in the next 2 years
Over 90.0% of the company shares are owned by institutional investors
On 8th of November 2022 Medifast paid $ 1.64 per share dividend to its current shareholders
Latest headline from Medifast Named to the 2022 FORTUNE 100 Fastest-Growing Companies List - Yahoo Finance

Medifast Upcoming and Recent Events

Earnings reports are used by Medifast to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Medifast previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Medifast Largest EPS Surprises

Earnings surprises can significantly impact Medifast's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Medifast SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Medifast prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Medifast investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Medifast specific information freely available to individual and institutional investors to make a timely investment decision.
8th of September 2022
Other Events
3rd of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
16th of June 2022
Financial Statements and Exhibits. Other Events. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
3rd of June 2022
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
1st of June 2022
Other Events
2nd of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
17th of March 2022
Financial Statements and Exhibits. Other Events
23rd of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition

Medifast Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Medifast is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Medifast backward and forwards among themselves. Medifast's institutional investor refers to the entity that pools money to purchase Medifast's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.5 K264 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.5 K250 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.5 K306 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.6 K308 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.6 K456 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares917194 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.2 K238 K
Note, although Medifast's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Medifast Market Capitalization

The company currently falls under 'Mid-Cap' category with total capitalization of 1.4 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Medifast's market, we take the total number of its shares issued and multiply it by Medifast's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Medifast Profitablity

Medifast's profitability indicators refer to fundamental financial ratios that showcase Medifast's ability to generate income relative to its revenue or operating costs. If, let's say, Medifast is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Medifast's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Medifast's profitability requires more research than a typical breakdown of Medifast's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of 9.44 %, which may imply that it executes well on its competitive polices and has reasonable control over its expenses and variable costs. This is very large. In the same way, it shows Net Operating Margin of 12.97 %, which entails that for every 100 dollars of revenue, it generated 0.13 of operating income.
Last ReportedProjected for 2022
Return on Investment 120.23  129.72 
Return on Average Assets 48.64  52.49 
Return on Average Equity 91.20  98.40 
Return on Invested Capital 3.37  2.82 
Return on Sales 0.14  0.14 

Management Efficiency

The entity has Return on Asset of 36.55 % which means that on every $100 spent on asset, it made $36.55 of profit. This is very large. In the same way, it shows return on shareholders equity (ROE) of 96.8 %, implying that it generated $96.8 on every 100 dollars invested. Medifast management efficiency ratios could be used to measure how well medifast manages its routine affairs as well as how well it operates its assets and liabilities. Medifast Return on Average Assets are projected to increase significantly based on the last few years of reporting. The past year's Return on Average Assets were at 48.64. The current year Return on Average Equity is expected to grow to 98.40, whereas Return on Invested Capital is forecasted to decline to 2.82. Medifast Current Assets are projected to increase significantly based on the last few years of reporting. The past year's Current Assets were at 306.87 Million. The current year Assets Non Current is expected to grow to about 98.7 M, whereas Revenue to Assets are forecasted to decline to 3.21.
Last ReportedProjected for 2022
Book Value per Share 17.30  14.30 
Enterprise Value over EBIT 11.00  13.79 
Enterprise Value over EBITDA 10.07  12.19 
Price to Book Value 12.02  10.82 
Tangible Assets Book Value per Share 34.03  36.72 
Enterprise Value2.3 B2.5 B
Tangible Asset Value398.3 M429.8 M

Technical Drivers

As of the 26th of November, Medifast secures the risk adjusted performance of (0.015904), and Mean Deviation of 2.25. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Medifast, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Medifast, which can be compared to its peers in the industry. Please verify Medifast coefficient of variation, maximum drawdown, skewness, as well as the relationship between the information ratio and downside variance to decide if Medifast is priced some-what accurately, providing market reflects its recent price of 120.17 per share. Given that Medifast has jensen alpha of (0.13), we recommend you to check Medifast's last-minute market performance to make sure the company can sustain itself at a future point.

Medifast Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Parabolic SAR indicator is used to determine the direction of Medifast's momentum and the point in time when Medifast has higher than normal probability directional change.

Medifast Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Medifast insiders, such as employees or executives, is commonly permitted as long as it does not rely on Medifast's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Medifast insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Medifast Predictive Daily Indicators

Medifast intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Medifast stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Medifast Forecast Models

Medifast time-series forecasting models is one of many Medifast's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Medifast's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Medifast Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Medifast prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Medifast shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Medifast. By using and applying Medifast Stock analysis, traders can create a robust methodology for identifying Medifast entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 14.17  12.25 
EBITDA Margin 14.55  13.23 
Gross Margin 73.89  82.18 
Profit Margin 10.75  9.04 

Current Medifast Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Medifast analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Medifast analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
347.0Strong Buy2Odds
Medifast current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Medifast analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Medifast stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Medifast, talking to its executives and customers, or listening to Medifast conference calls.
Medifast Analyst Advice Details

Medifast Stock Analysis Indicators

Medifast stock analysis indicators help investors evaluate how Medifast stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Medifast shares will generate the highest return on investment. By understating and applying Medifast stock analysis, traders can identify Medifast position entry and exit signals to maximize returns.
Quick Ratio0.32
Trailing Annual Dividend Rate4.52
Fifty Two Week Low96.00
Revenue Growth15.00%
Payout Ratio45.40%
Average Daily Volume Last 10 Day151.71k
Shares Short Prior Month601.7k
Average Daily Volume In Three Month164.06k
Earnings Growth-13.60%
Shares Percent Shares Out5.61%
Earnings Quarterly Growth-16.70%
Gross Margins72.75%
Forward Price Earnings7.78
Short Percent Of Float8.48%
Float Shares10.02M
Fifty Two Week High222.00
Fifty Day Average114.97
Enterprise Value To Ebitda5.88
Two Hundred Day Average156.11
Enterprise Value To Revenue0.76
Trailing Annual Dividend Yield3.77%
Additionally, see Correlation Analysis. Note that the Medifast information on this page should be used as a complementary analysis to other Medifast's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Medifast Stock analysis

When running Medifast price analysis, check to measure Medifast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medifast is operating at the current time. Most of Medifast's value examination focuses on studying past and present price action to predict the probability of Medifast's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Medifast's price. Additionally, you may evaluate how the addition of Medifast to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Is Medifast's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medifast. If investors know Medifast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medifast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
1.3 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Medifast is measured differently than its book value, which is the value of Medifast that is recorded on the company's balance sheet. Investors also form their own opinion of Medifast's value that differs from its market value or its book value, called intrinsic value, which is Medifast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medifast's market value can be influenced by many factors that don't directly affect Medifast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medifast's value and its price as these two are different measures arrived at by different means. Investors typically determine Medifast value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medifast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.